Table 2.

Primary and secondary outcomes

Outcome	MMF, n=41	Cyclophosphamide, n=43	P Value
Preliminary Outcome
Remission at 6 mo, n (%)	27 (66%)	35 (81%)	0.11
Secondary Outcome
Disease-free survival at 2 yr, n (%)	17 (43%)	25 (61%)	0.10
Disease-free survival at 4 yr, n (%)	6 (32%)	7 (39%)	0.17
Time to remission, wk, median (IQR)	7.3 [IQR, 3.7–11.7]	6.4 [IQR, 4.0–11.9]	0.85

MMF, mycophenolate mofetil; IQR, interquartile range.